Skip to main content

Table 5 Agreement and diagnostic performance of the significant serum markers

From: Identification of serum biomarker panel to differentiate malignant from benign thyroid nodules using multiplex bead assay

  BTNN/P MTN
N/P
Sensitivity
(%)
Specificity
(%)
PPV
(%)
NPV
(%)
Accuracy
IL-8 > 11.46 16/4 5/15 75 80 78.9 76.2 77.5
EGF > 30.24 17/3 3/17 85 85 85.0 85.0 85.0
HGF > 106.2 10/10 2/18 90 50 64.3 83.3 70.0
MIG > 623.8 19/1 9/11 55 95 91.7 67.9 75.0
Ang-1 > 45797 12/8 3/17 85 60 68.0 80.0 72.5
IL8 > 11.46
EGF > 30.24
13/7 1/19 95 65 73.08 92.86 80.0
IL8 > 11.46
EGF > 30.24
Ang-1 > 45797
12/8 1/19 95 60 70.37 92.31 77.5
IL8 > 11.46
EGF > 30.24
MIG > 623.8
13/7 1/19 95 65 73.08 92.86 80.0
IL8 > 11.46
EGF > 30.24
HGF > 106.2
9/11 0/20 100 45 64.52 100.0 72.50
IL-8 > 11.46
EGF > 30.24
HGF > 106.2
MIG > 623.8
9/11 0/20 100 45 64.52 100.0 72.50
  1. All serum values are expressed in pg/ml
  2. Ang-1 angiopoietin-1, AUC area under the curve, CI confidence intervals, EGF epidermal growth factor, HGF hepatocyte growth factor, IL-8 interleukin-8, MIG monokine induced by interferon gamma, BTN benign thyroid nodule, MTN malignant thyroid nodule, N/P number of “negative/positive” was assigned to patient who was below/above the cut-offs assigned by the Youden index, NPV negative predictive value, PPV positive predictive value